Innovation system

Marqus Hutchinson, Intelligent Waves’ CTO, Named Gold Medal Winner in 2024 Cybersecurity Excellence Awards

Retrieved on: 
onsdag, maj 29, 2024

Intelligent Waves (IW) , a leading tech integrator that delivers mission-focused multi-domain operational expertise and innovation to the Government through high-impact technology solutions, today announced that its own CTO, Marqus Hutchinson , has won the Gold Excellence Award for CTO of the Year in the 2024 Cybersecurity Excellence Awards .

Key Points: 
  • Intelligent Waves (IW) , a leading tech integrator that delivers mission-focused multi-domain operational expertise and innovation to the Government through high-impact technology solutions, today announced that its own CTO, Marqus Hutchinson , has won the Gold Excellence Award for CTO of the Year in the 2024 Cybersecurity Excellence Awards .
  • “We congratulate Marqus Hutchinson of Intelligent Waves on being recognized as an award winner in the Chief Technology Officer of the Year (CTO) category of the 2024 Cybersecurity Excellence Awards,” said Holger Schulze , CEO of Cybersecurity Insiders and founder of the 600,000-member Information Security Community on LinkedIn, which organizes the 9th annual Cybersecurity Excellence Awards.
  • “With over 600 entries across more than 300 categories, the awards are highly competitive.
  • Marqus was also instrumental in the recent CSFD contract win through his technologically disruptive leadership.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.

Retrieved on: 
onsdag, maj 29, 2024

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • LACRIFILL Canalicular Gel allows patient’s eyes to be bathed in their own natural tears.
  • “It’s been so exciting to be part of the launch of LACRIFILL Canalicular Gel, an interventional dry eye treatment that helps ophthalmologists with cataract, glaucoma and refractive surgeries and all of their dry eye needs.
  • Nordic Pharma is attending Kiawah Eye 2024 in Kiawah Island, SC from May 30-June 1 to share information about LACRIFILL Canalicular Gel and take orders.

ThreeD Capital Inc. Releases Results for the Three and Nine Months Ended March 31, 2024

Retrieved on: 
måndag, maj 27, 2024

The Company is in a strong position to capitalize on opportunities and trends in key industries including disruptive technology and digital asset sectors.

Key Points: 
  • The Company is in a strong position to capitalize on opportunities and trends in key industries including disruptive technology and digital asset sectors.
  • NAV is calculated as the value of total assets less the value of total liabilities divided by the total number of common shares outstanding as at a specific date.
  • The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies.
  • There is no comparable GAAP financial measure presented in ThreeD’s consolidated financial statements and thus no applicable quantitative reconciliation for such non-GAAP financial measure.

Orion Welcomes Industry Veteran Ron Pruitt to Executive Team

Retrieved on: 
tisdag, maj 21, 2024

Orion , the premier provider of transformative wealthtech solutions for fiduciary advisors, is pleased to announce the appointment of Ron Pruitt as its President of Orion Wealth Management, effective May 20.

Key Points: 
  • Orion , the premier provider of transformative wealthtech solutions for fiduciary advisors, is pleased to announce the appointment of Ron Pruitt as its President of Orion Wealth Management, effective May 20.
  • In this role, Ron will drive strategic initiatives to expand Orion's wealth management services and enhance its pioneering, investor-centric technology for financial advisors.
  • View the full release here: https://www.businesswire.com/news/home/20240521411660/en/
    Ron Pruitt, President of Orion Wealth Management.
  • He also co-founded and served as CIO for Placemark Investments and was a key executive at Envestnet after its acquisition.

MCE Systems Appoints Jim Hudak as Chief Strategy Officer

Retrieved on: 
tisdag, maj 21, 2024

MCE Systems Ltd. announces the appointment of Jim Hudak as Chief Strategy Officer.

Key Points: 
  • MCE Systems Ltd. announces the appointment of Jim Hudak as Chief Strategy Officer.
  • In this role, Jim will focus on building and strengthening MCE's existing channel partnerships and will spearhead MCE's AI initiatives.
  • "We’re thrilled to welcome Jim Hudak to the role of Chief Strategy Officer at MCE.
  • Hudak added: "I am excited to transition from a strategic advisor to MCE, into a full-time role, working alongside such a talented and innovative team.

LEO Satellite Market worth $23.2 Billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
tisdag, maj 14, 2024

However, space debris caused by LEO satellites and some regulatory challenges are expected to hinder market growth.

Key Points: 
  • However, space debris caused by LEO satellites and some regulatory challenges are expected to hinder market growth.
  • The LEO satellite market report includes small satellites (1–500 kg), medium satellites (500–1,000 kg), and large satellites (more than 1,000 kg).
  • In terms of satellite mass, the LEO satellite market is divided into four main categories: small satellites, medium satellites, CubeSats, and large satellites.
  • The Asia Pacific region is projected to be a high growth potential market for LEO satellite during the forecast period.

LEO Satellite Market worth $23.2 Billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
tisdag, maj 14, 2024

However, space debris caused by LEO satellites and some regulatory challenges are expected to hinder market growth.

Key Points: 
  • However, space debris caused by LEO satellites and some regulatory challenges are expected to hinder market growth.
  • The LEO satellite market report includes small satellites (1–500 kg), medium satellites (500–1,000 kg), and large satellites (more than 1,000 kg).
  • In terms of satellite mass, the LEO satellite market is divided into four main categories: small satellites, medium satellites, CubeSats, and large satellites.
  • The Asia Pacific region is projected to be a high growth potential market for LEO satellite during the forecast period.

Factoring Market size is set to grow by USD 1720.41 bn from 2023-2027, growing need for alternative sources of financing for msmes to boost the market growth, Technavio

Retrieved on: 
tisdag, maj 14, 2024

Factoring, an essential form of asset-based lending, facilitates the conversion of accounts receivable into immediate funds.

Key Points: 
  • Factoring, an essential form of asset-based lending, facilitates the conversion of accounts receivable into immediate funds.
  • The Factoring Market, represented by MAChinLeArning (ML) and Artificial Intelligence (AI), plays a crucial role in the financial industry.
  • Additionally, the increasing use of machine learning and AI in credit assessment and risk management enhances the efficiency and accuracy of factoring services.
  • Overall, the factoring market is a dynamic and evolving sector that continues to adapt to the changing needs of businesses and the financial industry.

Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
torsdag, maj 9, 2024

SAN CLEMENTE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2024, for the period ended March 31, 2024, and recent business highlights.

Key Points: 
  • First quarter revenue of $13.2M, +27% year-over-year growth; IFRS gross margin of 75.2%
    First quarter pulse recurring revenue of $4.7M, +118% year-over-year growth
    IFRS and non-IFRS operating loss narrowed to -$1.0M and -$0.4M, respectively; company approaching breakeven
    SAN CLEMENTE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2024, for the period ended March 31, 2024, and recent business highlights.
  • First Quarter Revenue of $13.2M; representing 27% year-over-year growth
    IFRS Operating Loss: $1.0M; down from $3.7 million in first quarter of 2023; *Non-IFRS Operating Loss: $0.4M
    Cash and Cash Equivalents as of March 31, 2024: $23.1M, Cash used in the first quarter of 2024 of $1.3M down from $3.0M in the first quarter of 2023.
  • Mr. Louis Scafuri, Sofwave CEO, commented, “We continue to experience significant tailwinds for our disruptive technology and unique business model, as demonstrated by the 27% top-line growth generated in the first quarter of 2024.
  • Of significance, recurring pulse sales are an increasingly significant contributor to our strong financial results, with recurring pulse sales representing more than one third of our total first quarter revenue.

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
tisdag, maj 7, 2024

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .